EXPERIENCE WITH 5-AZACITIDINE IN PATIENTS DIAGNOSED BY MYELODYSPLASTIC SYNDROMES OF INTERMEDIATE 2/HIGH RISK

被引：0
|
作者：
Llorente Dunia, De Miguel [1 ]
Lopez Nuria, Golbano [1 ]
Morfa Miguel, Diaz [1 ]
Juanis Jaime, Arbeteta [1 ]
Sanz Dolores, Morales [1 ]
Ramo Alejandro, Vazquez [1 ]
Maqueda Cristina, Fernandez [1 ]
Garcia Helga, Guillen [1 ]
Perez Dolores, Subira [1 ]
Martin Sonia, Herrero [1 ]
Albiz Blanca, Pinedo [1 ]
机构：
[1] Hosp Univ Guadalajara, Guadalajara, Jalisco, Mexico
来源：
HAEMATOLOGICA | 2016年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PB-076
引用
收藏
页码：341 / 341
页数：1
相关论文
共 50 条
  • [1] EXPERIENCE WITH THE USE OF 5-AZACITIDINE IN PATIENTS WITH MYELODYSPLASTIC SYNDROME OF LOW/INTERMEDIATE RISK
    Llorente Dunia, De Miguel
    Lopez Nuria, Golbano
    Morfa Miguel, Diaz
    Juanis Jaime, Arbeteta
    Sanz Dolores, Morales
    Perez Dolores, Subira
    Maqueda Cristina, Fernandez
    Ramo Alejandro, Vazquez
    Martin Sonia, Herrero
    Albiz Blanca, Pinedo
    [J]. HAEMATOLOGICA, 2016, 101 : 152 - 152
  • [2] SINGLE INSTITUTION EXPERIENCE OF 5-AZACITIDINE THERAPY IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIA
    Freyrie, A.
    Guidotti, F.
    Reda, G.
    Binda, F.
    Cortelezzi, A.
    [J]. HAEMATOLOGICA, 2012, 97 : 587 - 587
  • [3] The Prognostic Value of Monosomal Karyotype (MK) in High-Risk Patients with Myelodysplastic Syndromes Treated with 5-Azacitidine
    Papageorgiou, Sotirios
    Kontos, Christos K.
    Tsiambalis, Thomas
    Vyniou, Athina
    Symeonidis, Argiris
    Galanopoulos, Athanasios
    Kotsianidis, Ioannis
    Pappa, Vassiliki
    [J]. BLOOD, 2017, 130
  • [4] COMPASIVE USE OF 5-AZACITIDINE IN PATIENTS WITH LOW/INT-1 RISK MYELODYSPLASTIC SYNDROMES
    de Miguel, D.
    Golbano, N.
    San Roman, I.
    Arbeteta, J.
    Diaz, M.
    Morales, D.
    Herrero, S.
    Subira, D.
    PInedo, B.
    [J]. HAEMATOLOGICA, 2012, 97 : 581 - 581
  • [5] Pretransplantation 5-Azacitidine in High-Risk Myelodysplastic Syndrome
    Nishihori, Taiga
    Perkins, Janelle
    Mishra, Asmita
    Komrokji, Rami
    Kim, Jongphil
    Kharfan-Dabaja, Mohamed A.
    Perez, Lia
    Lancet, Jeffrey
    Fernandez, Hugo
    List, Alan
    Anasetti, Claudio
    Field, Teresa
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (06) : 776 - 780
  • [6] COMPASIVE USE OF 5-AZACITIDINE IN PATIENTS WITH LOW/INT-1 RISK MYELODYSPLASTIC SYNDROMES
    Dunia, D. M.
    Nuria, G.
    Miguel, D.
    Jaime, A.
    Helga, G.
    Dolores, S.
    Dolores, M.
    Blanca, P.
    Cristina, F.
    Alejandro, V.
    Sonia, H.
    [J]. HAEMATOLOGICA, 2016, 101 : 773 - 774
  • [7] FLOW CYTOMETRY PREDICTS TREATMENT OUTCOME IN INTERMEDIATE-2 AND HIGH RISK MYELODYSPLASTIC SYNDROME PATIENTS TREATED WITH 5-AZACITIDINE
    Alhan, C.
    Westers, T.
    Cali, C.
    Eeltink, C.
    Ossenkoppele, G.
    van de Loosdrecht, A.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 379 - 380
  • [8] Safety and efficacy of azacitidine in elderly patients with intermediate to high-risk myelodysplastic syndromes
    Navada, Shyamala C.
    Silverman, Lewis R.
    [J]. THERAPEUTIC ADVANCES IN HEMATOLOGY, 2017, 8 (01) : 21 - 27
  • [9] INFECTIOUS COMPLICATIONS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES/ACUTE MYELOID LEUKEMIA TREATED WITH 5-AZACITIDINE
    Ramos, S.
    Santos, M.
    Tenreiro, R.
    Pereira, M.
    Cortesao, E.
    Rito, L.
    Ribeiro, M. L.
    [J]. HAEMATOLOGICA, 2015, 100 : 474 - 475
  • [10] The Tolerability of Combination Therapy with Thalidomide and 5-Azacitidine in Patients with Advanced Myelodysplastic Syndromes (MDS).
    Kenealy, Melita K.
    Seymour, John F.
    Linda, Cowan
    Milner, Alvin
    Giri, Pratyush
    Ho, Shir-Jing
    Benson, Warwick
    Nicol, Andrew
    Campbell, Philip
    Prosser, Ian
    Underhill, Craig
    Cunningham, Ilona
    Mills, Anthony K.
    Szer, Jeffrey
    Presgrave, Peter
    Filshie, Robin
    [J]. BLOOD, 2009, 114 (22) : 695 - 695
12345